Introduction {#Sec1}
============

Insulin resistance and type 2 diabetes have been associated with excess lipid accumulation in non-adipose tissues such as skeletal muscle \[[@CR1], [@CR2]\] and liver \[[@CR3], [@CR4]\]. The mechanistic link between intracellular lipid overload and insulin resistance is believed to reside in the accumulation of lipid-derived intermediates, such as diacylglycerols and ceramides, which trigger activation of novel protein kinase C isozymes leading to impairments in insulin signalling \[[@CR5]\]. It remains unknown, however, whether the excess storage of lipids in insulin-resistant muscle and liver is a consequence of greater lipid uptake from the circulation, decreased lipid use through oxidation, release and/or secretion, or a combination of both.

Results from studies on intracellular lipid handling in insulin-resistant skeletal muscle and liver tissue are far from consistent. Lipid uptake in muscle of insulin-resistant and type 2 diabetic individuals and corresponding animal models has been reported to be either higher (mostly but not exclusively in postprandial conditions) \[[@CR6]--[@CR15]\], similar \[[@CR16]--[@CR20]\] or lower (mostly but not exclusively in postabsorptive conditions) \[[@CR9], [@CR21]--[@CR28]\] when compared with insulin-sensitive controls. Lipid oxidation in insulin-resistant or type 2 diabetic muscle has also been reported to be either lower \[[@CR9], [@CR17], [@CR18], [@CR20]--[@CR25], [@CR29]\] or unchanged \[[@CR6], [@CR7], [@CR14], [@CR19]\] when compared with healthy controls. Data on lipid uptake in insulin-resistant and type 2 diabetic liver tissue are scarce and have predominantly been obtained from animal models, showing either an increase \[[@CR12], [@CR21], [@CR30]\] or no significant difference \[[@CR8], [@CR20], [@CR31]\] compared with controls. Liver lipid secretion, as measured by the production of VLDL particles, is generally reported to be greater in an insulin-resistant or type 2 diabetic state \[[@CR32]--[@CR34]\]. Differences in study design, such as the nutritional state (postprandial vs postabsorptive conditions), can only explain part of the discrepancy in the literature. In addition, other factors, such as the stage of type 2 diabetes pathogenesis and the methodology applied to assess lipid handling, are likely to contribute to the apparent inconsistency.

Recently, we introduced the application of ^1^H-\[^13^C\] magnetic resonance spectroscopy (MRS) in combination with the oral administration of ^13^C-labelled lipids to determine in vivo postprandial lipid partitioning in skeletal muscle and liver tissue in rodents \[[@CR35]\]. ^1^H-\[^13^C\] MRS indirectly detects the ^13^C-labelled lipids through the attached ^1^H nuclei. After correction for the natural abundance of ^13^C, this allows the amount of lipids stored in the tissue originating from the dietary ^13^C-labelled lipids to be quantified. MRS is non-invasive and does not involve harmful radiation, allowing repeated measurements to follow the time course of uptake and depletion of ^13^C-labelled lipids in multiple tissues. We have shown that in healthy rats the uptake of ^13^C-labelled lipids was about tenfold higher in liver than in skeletal muscle \[[@CR35]\].

In this study we applied the ^1^H-\[^13^C\] MRS technique in prediabetic and diabetic rat models with the aim of gaining greater insight into the derangements in liver and skeletal muscle lipid handling at different stages during the pathogenesis of type 2 diabetes. Total and ^13^C-labelled lipid concentrations were measured in liver and skeletal muscle tissue at baseline, and at 4, 24 and 48 h after the oral administration of \[U-^13^C\]algal lipid mixture. Based on previous observations, we hypothesised that postprandial lipid handling is disturbed in both liver and skeletal muscle tissue of prediabetic rats, and that these disturbances are further exacerbated following the development of overt type 2 diabetes.

Methods {#Sec2}
=======

*Animals and study design* {#d29e540}
--------------------------

Four groups (*n* = 6) of male Zucker diabetic fatty (ZDF) rats (Charles River Laboratories, Sulzfield, Germany) were used for this study: (1) obese, prediabetic *fa*/*fa* rats at the age of 6 weeks; (2) lean, healthy *fa*/*+* littermates at the age of 6 weeks; (3) obese, diabetic *fa*/*fa* rats at the age of 12 weeks and (4) lean, healthy *fa*/*+* littermates at the age of 12 weeks \[[@CR36], [@CR37]\]. The rats were housed in pairs at 20°C and 50% humidity, on a 12 h light--dark cycle with free access to Purina 5008 diet (19 energy per cent \[En%\] from fat, 54 En% from carbohydrates and 27 En% from protein; SM R/M modified 5008 diet; Ssniff Spezialdiäten, Soest, Germany) and water during the entire period of the experiment. All experimental procedures were reviewed and approved by the local institutional animal care committee (Maastricht University, Maastricht, the Netherlands).

Before the administration of ^13^C-labelled lipids, ^1^H-\[^13^C\] MRS measurements were carried out on all rats to determine total (^12^C + ^13^C) and ^13^C-enriched intracellular lipid (ICL) concentrations in the tibialis anterior (TA) muscle (intramyocellular lipids, IMCL) and liver (intrahepatocellular lipids, IHCL) at baseline. Two days later, rats were orally administered 1.5 g \[U-^13^C\]algal lipid mixture (^13^C enrichment \> 98%; fatty acid composition: 53% palmitic acid, 9% palmitoleic acid, 28% oleic acid, and 6% linoleic acid; Cambridge Isotope Laboratories, Andover, MA, USA) per kg body weight. ^1^H-\[^13^C\] MRS measurements were performed at 4, 24 and 48 h after administration of ^13^C-labelled lipids.

Blood samples were taken from the vena saphena after each MRS experiment and were used for the determination of plasma glucose, NEFA and triacylglycerol (TAG) concentrations.

*MRS experiments* {#d29e618}
-----------------

During the MRS experiments, rats were anaesthetised using 1.5--2.5% isoflurane (IsoFlo; Abbott Laboratories, Maidenhead, UK). Body temperature was maintained at 37 ± 1°C using heating pads. All MRS experiments were performed on a 6.3 T horizontal Bruker MR system (Bruker, Ettlingen, Germany). In each rat, localised ^1^H-\[^13^C\] MRS was performed first on a 3.5 × 3.5 × 3.5 mm^3^ (in *fa*/*+* rats) or 3 × 3 × 3 mm^3^ (in *fa*/*fa* rats) voxel placed in the TA muscle (Fig. [1a,b](#Fig1){ref-type="fig"}) and, after repositioning, on a 4 × 2 × 4 mm^3^ voxel in the median lobe of the liver (Fig. [1c,d](#Fig1){ref-type="fig"}) using the LASER-POCE method as described previously \[[@CR35]\]. For each voxel, 64 water-suppressed LASER-POCE experiments, consisting of 16 averages each, were performed serially in an interleaved fashion with the ^13^C-editing pulse turned on every other experiment. An unsuppressed water spectrum, consisting of 16 averages, was recorded from the same voxel and was used as internal reference.Fig. 1T~1~-weighted transversal images of a *fa*/*+* rat left hindlimb with a 3.5 × 3.5 × 3.5 mm^3^ voxel in the TA muscle (**a**), a *fa*/*fa* rat left hindlimb with a 3 × 3 × 3 mm^3^ voxel in the TA muscle (**b**), a *fa*/*+* rat abdomen with a 4 × 2 × 4 mm^3^ voxel in the median lobe of the liver (**c**) and a *fa*/*fa* rat abdomen with a 4 × 2 × 4 mm^3^ voxel in the median lobe of the liver (**d**)

*MRS data analysis* {#d29e727}
-------------------

Spectra from the 32 LASER-POCE experiments with and without ^13^C editing were added separately and the difference spectrum was calculated using Matlab (R2009b; Mathworks, Natick, MA, USA). Water and ICL methylene (ICL-CH~2~ signal at 1.3 ppm) peak areas were quantified from the unsuppressed and suppressed spectra, respectively, using the jMRUI software package \[[@CR38]\] as described previously \[[@CR39]\]. Total (^12^C + ^13^C) and ^13^C-labelled ICL levels were determined from the LASER-POCE spectra without ^13^C editing and the difference spectra, respectively, and are presented as a percentage of the unsuppressed water signal measured in the same voxel. The average relative ^13^C enrichment determined at baseline was used to correct the ^13^C-labelled ICL levels at 4, 24 and 48 h after ^13^C-labelled lipid administration for natural abundance of ^13^C. Previously, we have shown that the in-vivo ^1^H-\[^13^C\] MRS determination of ^13^C enrichment of IHCL was in agreement with the ex-vivo analysis by gas chromatography--combustion-isotope ratio mass spectrometry (GC-C-IRMS) and that the 1.1% natural abundance of ^13^C could be reliably determined in both IMCL and IHCL pools \[[@CR35]\].

*Plasma analysis* {#d29e786}
-----------------

Blood samples were collected in K-EDTA-coated tubes at baseline and at 4, 24 and 48 h after ^13^C-labelled lipid administration, centrifuged for 10 min at 1,000 *g*, and portioned plasma volumes were frozen in liquid nitrogen and stored at −80°C. Concentrations of plasma glucose, NEFA and TAG were determined using an automatic glucometer (FreeStyle; Abbott, Abbott Park, IL, USA), the NEFA-HR(2) kit (Wako Chemicals, Neuss, Germany) and the serum TAG determination kit (Sigma-Aldrich, Zwijndrecht, the Netherlands), respectively.

*Statistics* {#d29e798}
------------

All data (*n* = 6 per group) are expressed as means ± SEM. Data were analysed using mixed-model repeated-measures ANOVA with time point (baseline and 4, 24 and 48 h post) as the within-subject factor, and age (6 and 12 weeks) and genotype (*fa*/*+* and *fa*/*fa*) as between-subject factors. Only if the interaction term between the factors was found to be significant, the effect of each factor was analysed separately using one-way ANOVA (time point) or unpaired Student's *t* tests (age and genotype). Bonferroni corrections were applied when appropriate. Statistical analyses were performed using the IBM SPSS statistics software package (SPSS, version 19, Chicago, IL, USA). The level of significance was set at *p \<* 0.05.

Results {#Sec3}
=======

*Body weight* {#d29e829}
-------------

The body weight of *fa*/*fa* rats was 18% higher than that of *fa*/*+* rats (*p \<* 0.001), independent of age (Table [1](#Tab1){ref-type="table"}). Rats at 12 weeks of age were 95% heavier than rats at 6 weeks of age (*p \<* 0.001), independent of genotype. The amount of ^13^C-labelled lipids that was administered to the rats was scaled to body weight (Table [1](#Tab1){ref-type="table"}).Table 1Body weight of rats and amount of ^13^C-labelled lipid mixture administeredBody weight/amount of lipid administered6 weeks12 weeks*fa*/*+fa*/*fafa*/*+fa*/*fa*Body weight (g)166 ± 7190 ± 12\*\*\*319 ± 10^†††^374 ± 11\*\*\*^,†††13^C-labelled algal lipid mixture (mg)247 ± 26286 ± 43\*\*\*478 ± 15^†††^563 ± 17\*\*\*^,†††^Data are means ± SEM\*\*\**p \<* 0.001, compared with *fa*/*+*; ^†††^*p \<* 0.001, compared with 6 weeks

*Plasma glucose, NEFA and TAG* {#d29e981}
------------------------------

Results of the plasma analyses are shown in Table [2](#Tab2){ref-type="table"}. Plasma glucose concentrations were higher in *fa*/*fa* rats compared with *fa*/*+* rats independent of time point both at 6 (12.2 ± 0.7 vs 7.3 ± 0.3 mmol/l, *p \<* 0.001) and 12 (18.9 ± 0.8 vs 6.9 ± 0.3 mmol/l, *p \<* 0.001) weeks of age. In diabetic *fa*/*fa* rats at 12 weeks of age, plasma glucose was 50% higher when compared with the prediabetic *fa*/*fa* rats at 6 weeks of age independent of time point (*p \<* 0.01). The administration of ^13^C-labelled lipids did not affect plasma glucose levels after 4, 24 and 48 h in any group (*p* = 0.296). At 6 weeks of age, plasma NEFA concentrations did not differ between prediabetic *fa*/*fa* rats and their control littermates (*p* = 0.820). In contrast, at 12 weeks of age, plasma NEFA concentrations in diabetic *fa*/*fa* rats were 86% higher than in *fa*/*+* rats independent of time point (*p \<* 0.05). Plasma NEFA at 4 and 24 h after the administration of ^13^C-labelled lipids was not significantly different from baseline, but at 48 h after ^13^C-labelled lipid administration it had decreased by as much as 60 ± 6% when compared with the earlier time points in all groups. Plasma TAG concentrations were higher in *fa*/*fa* rats compared with *fa*/*+* rats, independent of age and time point (1.64 ± 0.10 vs 0.43 ± 0.02 mmol/l, *p \<* 0.001). The administration of ^13^C-labelled lipids did not affect plasma TAG levels after 4, 24 and 48 h in any group.Table 2Plasma glucose, NEFA and TAG concentrations at baseline and 4, 24 and 48 h after oral administration of the ^13^C-labelled lipid mixture to ratsVariable6 weeks12 weeks*fa*/*+fa*/*fafa*/*+fa*/*fa*Plasma glucose (mmol/l)  Baseline7.0 ± 0.311.8 ± 1.3\*\*\*7.5 ± 0.317.7 ± 1.7\*\*\*^,††^  4 h post7.2 ± 0.411.0 ± 0.9\*\*\*6.5 ± 0.718.9 ± 2.2\*\*\*^,††^  24 h post6.9 ± 0.113.5 ± 0.8\*\*\*7.0 ± 0.220.7 ± 0.3\*\*\*^,††^  48 h post8.1 ± 1.212.6 ± 2.2\*\*\*6.5 ± 0.718.4 ± 1.3\*\*\*^,††^Plasma NEFA (mmol/l)  Baseline0.32 ± 0.030.38 ± 0.060.24 ± 0.040.44 ± 0.04\*  4 h post0.28 ± 0.040.29 ± 0.040.22 ± 0.060.50 ± 0.09\*  24 h post0.35 ± 0.050.26 ± 0.050.27 ± 0.070.34 ± 0.05\*  48 h post0.15 ± 0.05^‡‡‡,§,¶^0.13 ± 0.02^‡‡‡,§,¶^0.08 ± 0.02^‡‡‡,§,¶^0.26 ± 0.08\*^,‡‡‡,§,¶^Plasma TAG (mmol/l)  Baseline0.47 ± 0.051.54 ± 0.30\*\*\*0.45 ± 0.021.52 ± 0.20\*\*\*  4 h post0.40 ± 0.031.66 ± 0.34\*\*\*0.52 ± 0.051.51 ± 0.23\*\*\*  24 h post0.33 ± 0.051.28 ± 0.18\*\*\*0.36 ± 0.051.39 ± 0.09\*\*\*  48 h post0.42 ± 0.051.97 ± 0.31\*\*\*0.47 ± 0.062.16 ± 0.34\*\*\*Data are means ± SEM\**p* \< 0.05, \*\*\**p* \< 0.001 compared with *fa*/*+*; ^††^*p* \< 0.01, compared with 6 weeks; ^‡‡‡^*p* \< 0.001, compared with baseline; ^§^*p* \< 0.05, compared with 4 h post lipid administration; ^¶^*p* \< 0.05, compared with 24 h post lipid administration

*MRS data* {#d29e1410}
----------

Figure [2](#Fig2){ref-type="fig"} displays typical examples of water-suppressed LASER-POCE spectra acquired from TA muscle and liver at 4 h after the administration of ^13^C-labelled lipids in a healthy *fa*/*+* rat and a diabetic *fa*/*fa* rat at 12 weeks of age. The lipid methylene signal at 1.30 ppm in the normal ^1^H spectra without the ^13^C-editing pulse was used for quantification of total (^12^C + ^13^C) IMCL and IHCL. The difference spectra, resulting from the subtraction of the experiments with and without the ^13^C-editing pulse, only contain signals from ^1^H-^13^C coupled resonances and were used to determine the ^13^C enrichment of the IMCL and IHCL pools.Fig. 2Typical examples of LASER-POCE spectra from TA muscle (**a**, **b**) and liver (**c**, **d**) from a healthy *fa*/*+* rat (**a**, **c**) and a diabetic *fa*/*fa* rat (**b**, **d**) at 12 weeks of age. Spectra were acquired 4 h after the oral administration of 1.5 g \[U-^13^C\]algal lipid mixture per kg body weight. LASER-POCE spectra without ^13^C editing, with ^13^C editing and the calculated difference spectra containing only ^13^C-coupled ^1^H resonances (5 × magnification) are shown. Peak annotations: tCr, total creatine; EMCL, extramyocellular lipids; Cho, choline

Total IMCL and IHCL concentrations at baseline and 4, 24 and 48 h after oral administration of the \[U-^13^C\]algal lipid mixture in *fa*/*+* and *fa*/*fa* rats at 6 and 12 weeks of age are shown in Fig. [3](#Fig3){ref-type="fig"}. Data are expressed as percentage of the unsuppressed water signal measured in the same voxel. At both ages, total IMCL and IHCL content were higher in *fa*/*fa* rats compared with *fa*/*+* rats. In *fa*/*fa* rats, IMCL content was 73% higher at 12 weeks compared with 6 weeks (*p \<* 0.001), whereas in *fa*/*+* rats IMCL was 43% lower at 12 weeks than at 6 weeks (*p \<* 0.001). IHCL content was 48% higher at 12 weeks of age compared with 6 weeks, independent of genotype (*p \<* 0.05). The administration of ^13^C-labelled lipids did not affect total IMCL and IHCL levels, except for a very slight decrease in IMCL in all groups at 48 h after administration, which is probably related to the decrease in plasma NEFA concentration at this time point.Fig. 3Total (^12^C + ^13^C) intracellular lipid content in TA muscle (IMCL; **a**, **b**) and liver (IHCL; **c**, **d**) of *fa*/*+* rats (black bars) and *fa*/*fa* rats (white bars) at 6 (**a**, **c**) and 12 (**b**, **d**) weeks of age measured at baseline and at 4, 24 and 48 h after the oral administration of \[U-^13^C\]algal lipid mixture (*n* = 6 per group). Data are expressed as a mean percentage of the unsuppressed water signal ± SEM. IMCL content in *fa*/*+* rats and *fa*/*fa* rats at 12 weeks was significantly different from 6 weeks, independent of time point (*p* \< 0.05). IHCL content was significantly higher at 12 weeks than at 6 weeks, independent of genotype and time point (*p* \< 0.05). \*\*\**p* \< 0.001, compared with *fa*/*+* rats; ^†^*p* \< 0.05, compared with baseline; ^‡^*p* \< 0.05, compared with 24 h post lipid administration

The relative ^13^C enrichments of IMCL and IHCL measured at baseline were 1.19 ± 0.04% and 1.39 ± 0.06%, respectively, both independent of genotype and age. These values were used to correct ^13^C-labelled IMCL and IHCL levels at 4, 24 and 48 h after the administration of ^13^C-labelled lipids for natural abundance of ^13^C and the results are shown in Fig. [4](#Fig4){ref-type="fig"}. Thus, ^13^C-enriched IMCL and IHCL concentrations in Fig. [4](#Fig4){ref-type="fig"} represent the amount of lipids stored in muscle and liver originating from the administered ^13^C-labelled lipids.Fig. 4^13^C-enriched intracellular lipid content in TA muscle (IMCL; **a**, **b**) and liver (IHCL; **c**, **d**) of *fa*/*+* rats (black bars) and *fa*/*fa* rats (white bars) at 6 (**a**, **c**) and 12 (**b**, **d**) weeks of age determined at 4, 24 and 48 h after the oral administration of \[U-^13^C\]algal lipid mixture (*n* = 6 per group). Data are expressed as a mean percentage of the unsuppressed water signal ± SEM. ^13^C-enriched IMCL content in *fa*/*+* rats at 4 h was significantly lower at 12 weeks than at 6 weeks (*p* \< 0.05), whereas in *fa*/*fa* rats ^13^C-enriched IMCL content was significantly higher at 12 weeks than at 6 weeks for each time point (*p* \< 0.05). ^13^C-enriched IHCL content was significantly higher at 12 weeks than at 6 weeks, independent of genotype and time point (*p* \< 0.05). \**p* \< 0.05, compared with *fa*/*+* rats; ^†^*p* \< 0.05, compared with 4 h post lipid administration; ^‡^*p* \< 0.05, compared with 24 h post lipid administration

At 6 weeks of age, ^13^C-labelled IMCL content at 4 h after administration of ^13^C-labelled lipids was 31% lower in *fa*/*fa* rats than in *fa*/*+* rats (*p \<* 0.05), indicating a lower postprandial muscle lipid uptake in prediabetic rats compared with controls (Fig. [4a](#Fig4){ref-type="fig"}). In *fa*/*+* rats at 12 weeks of age, ^13^C-labelled IMCL content 4 h post lipid administration was 44% lower compared with the content in *fa*/*+* rats at 6 weeks (*p \<* 0.05), implying that in control rats muscle lipid uptake decreased with ageing (Fig. [4a,b](#Fig4){ref-type="fig"}). In contrast, in diabetic *fa*/*fa* rats at 12 weeks of age, ^13^C-labelled IMCL at 4 h post lipid administration was 217% higher compared with prediabetic *fa*/*fa* rats at 6 weeks (*p \<* 0.01), resulting in a 243% higher ^13^C enrichment of IMCL at 4 h in comparison with *fa*/*+* controls of the same age (*p \<* 0.05) (Fig. [4a,b](#Fig4){ref-type="fig"}). In all groups, the ^13^C enrichment of IMCL decreased as a function of time between 4 and 48 h after administration. However, in contrast to control *fa*/*+* rats, ^13^C-labelled IMCL in *fa*/*fa* rats at both ages only started to decline at 48 h post lipid administration and did not significantly decrease between 4 and 24 h, indicating a prolonged uptake or a decreased turnover of the ^13^C-labelled lipids in prediabetic and diabetic muscle (Fig. [4a,b](#Fig4){ref-type="fig"}).

At 4 h after the oral administration of ^13^C-labelled lipids, the ^13^C enrichment of IHCL was 2.3-fold greater in *fa*/*fa* rats compared with *fa*/*+* rats (*p \<* 0.001), independent of age, implying that postprandial liver lipid uptake was greater in both prediabetic and diabetic rats compared with controls (Fig. [4c,d](#Fig4){ref-type="fig"}). At 12 weeks of age, ^13^C-labelled IHCL content was ∼50% higher compared with the content at 6 weeks of age (*p \<* 0.05), independent of genotype and time point (Fig. [4c,d](#Fig4){ref-type="fig"}). In all groups, the ^13^C enrichment of IHCL at 24 and 48 h was lower than at 4 h after the administration of ^13^C-labelled lipids (*p \<* 0.001), but it was always higher in *fa*/*fa* rats than in *fa*/*+* rats (*p \<* 0.001) (Fig. [4c,d](#Fig4){ref-type="fig"}).

Discussion {#Sec4}
==========

This study aimed to clarify whether intracellular lipid accumulation in insulin-resistant and diabetic liver and skeletal muscle tissue is a consequence of increased lipid uptake, decreased lipid use, or a combination of both. Using non-invasive ^1^H-\[^13^C\] MRS combined with the oral administration of a ^13^C-labelled lipid mixture \[[@CR35]\], we showed that in vivo postprandial lipid uptake in liver in both prediabetic and diabetic rats was greater than the uptake in healthy, insulin-sensitive controls, while liver lipid use was not affected. Whereas skeletal muscle appeared to be protected from excess lipid uptake in the prediabetic state, muscle lipid uptake was massively increased following the development of overt type 2 diabetes. Skeletal muscle lipid turnover was significantly reduced in prediabetic and diabetic rats.

In this study, we used the ZDF rat as an animal model of type 2 diabetes. We, as well as others, have previously shown that *fa*/*fa* ZDF rats progress from prediabetes to overt type 2 diabetes in a highly predictable age-dependent fashion \[[@CR37], [@CR40]\]. At the age of 6 weeks, *fa*/*fa* rats are in an insulin-resistant, prediabetic state characterised by normal plasma glucose levels in fasting conditions, slightly increased plasma glucose levels in the fed state, normal plasma NEFA but elevated plasma insulin and TAG levels \[[@CR37], [@CR40]\], which was confirmed in the present study. Between 8 and 10 weeks of age, *fa*/*fa* rats progress from a normoglycaemic--hyperinsulinaemic to a hyperglycaemic--hyperinsulinaemic state \[[@CR37], [@CR40]\]. In this study, we confirmed that the *fa*/*fa* rats at 12 weeks of age developed overt type 2 diabetes. Heterozygous *fa*/*+* rats remained normoglycaemic and normoinsulinaemic and served as healthy controls \[[@CR37], [@CR40]\].

In liver of prediabetic and diabetic *fa*/*fa* rats, the lipid content was 5.6-fold greater when compared with the healthy controls and this was accompanied by a 2.3-fold greater dietary lipid uptake in the liver 4 h after lipid administration. These data are in accordance with previous observations of elevated lipid uptake in insulin-resistant and diabetic liver \[[@CR8], [@CR12], [@CR20], [@CR21], [@CR30]\]. During periods of high lipid influx, such as during the immediate postprandial period, the liver acts as a systemic lipid buffer by taking up NEFA from the spillover pathway and chylomicron remnants, which are later re-secreted back into the circulation as VLDL \[[@CR41], [@CR42]\]. It has been suggested that in the insulin-resistant state, a greater proportion of meal derived fatty acids may be handled by the liver in the postprandial period \[[@CR42]\], which is consistent with our data of increased hepatic lipid uptake in prediabetic and diabetic rats. Relative decreases in ^13^C-labelled IHCL content between 4 and 48 h after administration of ^13^C-labelled lipids were similar for all groups, indicating that liver lipid turnover was largely unaffected in prediabetic and diabetic rats when compared with the healthy controls.

Between 6 and 12 weeks of age, liver lipid content increased in both *fa*/*fa* and *fa*/*+* rats by 48%, which was accompanied by a 62% higher uptake of dietary lipids in the liver, also independent of genotype. These increases in liver lipid content and uptake can therefore be ascribed to a general effect of ageing and are not necessarily specific for the transition from prediabetes to overt type 2 diabetes in *fa*/*fa* rats. In addition, the greater liver lipid uptake at 12 weeks could be due to the twofold higher amount of ^13^C-labelled lipids that was administered to the rats at 12 weeks compared with rats at 6 weeks of age. However, at 4 h after intake of the ^13^C-labelled lipids, the relative increase in liver lipid uptake in *fa*/*+* rats between 12 and 6 weeks of age was much larger than in *fa*/*fa* rats. This might indicate that in diabetic rats the maximum lipid buffer capacity of the liver is reached during the early postprandial period (\< 4 h), exposing other tissues, such as skeletal muscle, to increased plasma TAG and NEFA fluxes.

In addition to the steatotic liver, prediabetic *fa*/*fa* rats also had 2.3-fold higher intracellular lipid levels in skeletal muscle when compared with the healthy controls. However, the greater IMCL content in prediabetic rats was not associated with excess postprandial muscle lipid uptake. In contrast to the highly elevated postprandial lipid uptake in liver, the uptake of dietary lipids in muscle at 4 h after intake was 31% lower in prediabetic rats when compared with the healthy controls. This result is in quantitative agreement with data from previous studies in insulin-resistant obese Zucker rats using orally administered ^14^C-labelled lipids \[[@CR20], [@CR21]\]. However, in contrast to these reports and our own data, other studies have shown an increased postprandial muscle lipid uptake in insulin-resistant individuals and animals \[[@CR8], [@CR11], [@CR15]\]. In addition, in vitro measurements in isolated muscle preparations and giant sarcolemmal vesicles yielded increased lipid uptake rates in muscle from insulin-resistant obese individuals and obese Zucker rats \[[@CR7], [@CR10], [@CR13], [@CR14]\]. Whereas fatty acid concentrations in these in vitro experiments were identical for insulin-resistant and control muscle, muscle of prediabetic rats in our in-vivo studies was exposed to fourfold higher plasma TAG levels compared with controls. The amount of ^13^C-labelled lipids that was administered to the rats was scaled to body weight, but was only 1.2-fold higher in prediabetic rats than in controls. Therefore, the ^13^C-labelled lipids are likely to be more diluted in the plasma of prediabetic rats compared with controls, which might have resulted in an underestimation of the in vivo muscle lipid uptake in prediabetic rats. Unfortunately, we lack information about the ^13^C enrichment of plasma TAG, because it was not possible to extract the lipid fraction from the small blood samples obtainable from rats, which is required for GC-C-IRMS. The lower lipid uptake in muscle of prediabetic rats as observed in the current study suggests that, after the initial buffering by the liver, more of the dietary lipids are shunted toward adipose tissue storage. Previous studies have indeed shown that upregulation of adipocyte lipid uptake is an early event in ZDF rats \[[@CR31]\] and that in obese Zucker rats the majority of dietary lipids are directed toward storage in adipose tissue \[[@CR20], [@CR21]\].

Between 6 and 12 weeks of age, intracellular lipid content in skeletal muscle decreased by 43% in *fa*/*+* rats, whereas it increased by 73% in *fa*/*fa* rats. These age-dependent changes in IMCL content are in excellent agreement with our previous study in ZDF rats \[[@CR40]\]. The decreased IMCL content in *fa*/*+* rats at 12 weeks of age was accompanied by a 44% lower dietary lipid uptake at 4 h after administration compared with *fa*/*+* rats at 6 weeks of age. In diabetic *fa*/*fa* rats at 12 weeks, on the other hand, the increased IMCL content was associated with a 217% higher dietary lipid uptake at 4 h compared with prediabetic *fa*/*fa* rats at 6 weeks of age. As a result, postprandial lipid uptake in muscle of diabetic rats was 3.4-fold higher when compared with controls, which is in accordance with previous reports of increased muscle lipid uptake in patients with type 2 diabetes during postprandial conditions \[[@CR6], [@CR9], [@CR12]\]. In contrast, during postabsorptive conditions, muscle lipid uptake has generally been found to be decreased in type 2 diabetes patients \[[@CR9], [@CR22], [@CR23], [@CR25]\].

The elevated uptake of dietary lipids in diabetic muscle is in sharp contrast with the lower muscle lipid uptake in prediabetic rats when compared with insulin-sensitive controls. Our data on liver lipid uptake suggest that in diabetic rats the maximum lipid buffer capacity of the liver has been reached, which might expose skeletal muscle to greater plasma TAG and NEFA fluxes in the immediate postprandial period, leading to an increase in muscle lipid uptake. Alternatively, the increased postprandial muscle lipid uptake after the progression from prediabetes to overt type 2 diabetes could also be due to changes at the level of skeletal muscle itself. In type 2 diabetes, hyperinsulinaemia increases skeletal muscle lipoprotein lipase activity \[[@CR43]\], which could lead to an increased fatty acid delivery to the diabetic muscle. Fatty acid transport into the myocyte is largely mediated by proteins, of which fatty acid translocase CD36 (FAT/CD36) plays a key role \[[@CR44]\]. The increased fatty acid uptake in giant sarcolemmal vesicles from muscle of type 2 diabetic patients and obese Zucker rats could, however, not be explained by an increased production of FAT/CD36 \[[@CR7], [@CR10]\]. Instead, the increase in fatty acid transport was associated with an increased abundance of FAT/CD36 at the plasma membrane \[[@CR7], [@CR10]\]. Our findings of reduced muscle lipid uptake in prediabetic rats and increased lipid uptake in muscle of rats with overt type 2 diabetes suggest that during the progression from prediabetes to diabetes, the expression and/or plasmalemmal content of FAT/CD36 has been increased. Indeed, in giant sarcolemmal vesicles from red muscle of ZDF rats there was a marked increase in both protein production and plasmalemmal content of FAT/CD36 between 6 and 12 weeks of age \[[@CR45]\]. However, in white muscle this upregulation was completely absent \[[@CR45]\]. Rat TA muscle is composed of a red region and a white region and the MRS voxel contained both red and white muscle. Therefore, while our results might not be universally true for all muscle types, they might be representative for mixed muscles, such as most human skeletal muscles.

In contrast to findings in healthy control rats, ^13^C-labelled IMCL in prediabetic and diabetic rats did not significantly decrease between 4 and 24 h after the administration of ^13^C-labelled lipids, indicating lower lipid oxidation. Daily activity levels are very similar in *fa*/*+* and *fa*/*fa* rats \[[@CR46]\] and therefore the lower lipid turnover in *fa*/*fa* rats is likely the result of an impairment in lipid oxidation. These results are in accordance with previous reports of reduced lipid oxidation in insulin-resistant and type 2 diabetic muscle \[[@CR9], [@CR17], [@CR18], [@CR20]--[@CR25], [@CR29]\].

In conclusion, we have shown that in both prediabetic and diabetic rats, total lipid contents in skeletal muscle and liver are substantially higher than in healthy controls. In the liver, this is accompanied by a highly elevated in-vivo postprandial lipid uptake in both prediabetic and diabetic rats. In contrast, skeletal muscle of prediabetic rats is protected from excess lipid uptake and muscle lipid uptake is only elevated following the development of overt diabetes. Our data suggest that the accumulation of lipids in prediabetic muscle is mainly attributed to impaired lipid oxidation, whereas lipid uptake is strongly increased following the development of an overt type 2 diabetic state.
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